Publisher's Synopsis
This book offers state-of-the-art vistas on an exciting new class of antidepressant drugs, e.g. reversible (short-acting) and selective type-A monoamine oxidase (MAO-A) inhibitors. A well-assorted cohort of preclinical and clinical investigators illustrate several relevant aspects of the MAO-A, dwelling on their antidepressant effects in various subgroups of patients suffering from endogenous, exogenous or atypical depressive disorders. Because of their high tolerance and mild side effect profile, MAO-A inhibitors appear to have a wider gamut of therapeutic potential in psychiatry than tricyclic antidepressants. The impressive array of evidence presented in this book convincingly demonstrates that the new generation of reversible MAO-A inhibitors are effective antidepressants with less side effects than available tricyclic antidepressant drugs.
